Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
124.33
-1.51 (-1.20%)
At close: Dec 1, 2025, 4:00 PM EST
124.07
-0.26 (-0.21%)
After-hours: Dec 1, 2025, 7:59 PM EST
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.77B in the quarter ending September 30, 2025, with 2.97% growth. This brings the company's revenue in the last twelve months to $29.09B, up 2.78% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$29.09B
Revenue Growth
+2.78%
P/S Ratio
5.33
Revenue / Employee
$1,652,670
Employees
17,600
Market Cap
154.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GILD News
- 6 days ago - Gilead Sciences: About To Break Out - Seeking Alpha
- 7 days ago - Gilead Foundation Commits Over $3 Million to Address Food Insecurity - Business Wire
- 11 days ago - Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength - Seeking Alpha
- 11 days ago - $100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield - Seeking Alpha
- 11 days ago - Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs - PRNewsWire
- 12 days ago - Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 13 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 13 days ago - Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa - Business Wire